Press Releases

    • SEP 27 2016

    Oncoceutics Receives Additional US Patent For ONC201 in Adenocarcinomas

    Philadelphia, PA (September 27, 2016) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #9,452,165 for the use of ONC201 to treat cancers that are categorized as adenocarcinomas. Adenocarcinomas are cancers that form from epithelial cells with glandular origins or characteristics. They represent approximately 50% of all cancers,

    • SEP 15 2016

    Oncotarget Article Describes Development of Imipridone ONC201

    Philadelphia, PA (September 15, 2016) – Oncoceutics, Inc. announced the publication of a review article in the journal Oncotarget entitled “Discovery and clinical introduction of first-in-class imipridone ONC201.” The article summarizes the history of how the molecule was discovered, its mechanism of action, and its preclinical profile, as well as its move into the clinic

    • SEP 08 2016

    ONC201 Continues to Show Excellent Safety When Dosed Weekly

    Philadelphia, PA (September 8, 2016) – Oncoceutics, Inc. announced the successful completion of the dose escalation phase of a clinical trial for the company’s lead molecule ONC201 using weekly dosing.  Oncoceutics has previously reported the exceptional safety profile for ONC201 in multiple clinical trials using a dosing regimen of once every three weeks. The weekly

    • AUG 16 2016

    Oncoceutics Awarded FDA Orphan Grant for ONC201 Multiple Myeloma Trial

    Philadelphia, PA (August 16, 2016) – Oncoceutics announced that it has been awarded an orphan grant from the U.S. Food and Drug Administration (FDA) to evaluate its lead molecule, ONC201, a selective antagonist of DRD2 that belongs to the superfamily of G protein-coupled receptors (GPCRs), in a multiple myeloma clinical trial. The award totals $1.7